Anthera Update (1-19-13)

Anthera announced last week that they priced a public offering of 60 million shares at $0.66 per share, which will add $40 million to their balance sheet.  Jefferies is acting as sole book-running manager in the offering and Leerink Swann is acting as co-manager.  These are quality investment banks and it is an impressive accomplishment for[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Pacira Update (1-18-13)

On a positive note, Pacira pre-released some of their key Q4 financials. The company expects Q4:12 and FY12 revenues to come in above Wall Street consensus estimates, driven by higher net sales of Exparel.  Q4 sales of the drug are targeted at $7.8 million, and total revenues are estimated at $10.5 million, compared to $4.2[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Incyte Update (1-18-13)

Incyte’s stock has had a nice move to start the year. The company presented at JP Morgan and did a good job of detailing how they will grow Jakafi sales.  Importantly, some on Wall Street also believe that INCY has learned a lot from the launch over the last year and are positioned to grow[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

ImmunoGen Update (1-18-13)

With T-DM1 FDA approval nearing the goal line – the PDUFA date is February 26 – ImmunoGen will join the ranks of commercially successful biotech companies, a major achievement. While it is widely known that the royalty rate IMGN will receive from partner Roche (~3%) is unlikely to lead the company to major profitability, regulatory[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Pharmacyclics Update (1-18-13)

We attended the Pharmacyclics‘ presentation and breakout session at JP Morgan. While the company repeated much of the powerful ASH data from a month earlier, we did learn some new and not unimportant pieces of information.  First, the company is about to open RESONATE 17 – a likely fast-track registration trial of ibrutinib (the fourth[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (1-18-13)

Isis’ stock has been strong, pre- and post-JP Morgan. Wall Street is beginning to warm up to the story, as we believe; the deep pipeline from late-stage to early-stage compounds is attracting more investors.  The recent partnerships with Biogen and AstraZeneca for certain early-stage drug development candidates have convinced some that antisense has real potential. The[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Sangamo Update (1-18-13)

Sangamo’s stock has risen sharply (~35%) since their presentation last week at the JP Morgan conference. The company broadly explained what their novel technology – In Vivo Protein Replacement – has the ability to accomplish.  It has the ability to mechanistically, physically, and permanently change a single disease related gene (“monogenic”) and, therefore, has substantial[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Alkermes Update (1-18-13)

OUTLOOK 2013 – RAISING BUY LIMIT AND TARGET PRICE Over the past decade, Alkermes has evolved into a fully integrated company as they receive revenue from five ALKS-developed approved drugs and have established a real R&D pipeline. ALKS has emerged as a leader in the development of injectable antipsychotics that can be administered as infrequently[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Anthera Update (1-18-13)

Anthera has switched gears as they recently disclosed that development program testing blisibimod in lupus is on hold as the company searches for a partner that will fund further development. This is a disappointment as ANTH had previously planned to start Phase III development for lupus this year.  ANTH now says that that they are[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue #746

January 18, 2013 Below is a pdf for Issue 746 of the Medical Technology Stock Letter. [gview file=”http://50.87.166.114/wp-content/uploads/2013/03/MTSL-746-January-18-2013-3.pdf” save=”1″]    

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Celgene Update (1-18-13)

OUTLOOK 2013, RAISING BUY LIMIT AND TARGET PRICE As recently as the summer of 2012, Celgene had a stable but slowing core business led by Revlimid but no apparent pipeline.  Questions arose about the company’s long-term growth. In a remarkable turn of events, the company and stock have been revived by not one but three[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Coronado Update (1-18-13)

Our #1 pick for 2013 We met with Coronado Biosciences’ new CEO Harlan Weisman during JP Morgan. We have known Dr. Weisman since our days as a Centocor analyst in the 1990s where he was Chief Medical Officer and subsequently became Senior management at Johnson & Johnson (JNJ) after its acquisition of CNTO.  With his[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by